Xingyu Lu

Semi-supervised learning with dynamic classifier selection for PMI estimation: An animal study

Jian Li, Yan-juan Wu, Xingyu Lu, Shurui Zhang et autres

cn (code pays fourni par la source)

HRRP Data Augmentation Based on Conditional Generative Adversarial Networks

Liao Wei, Zhe Wang, Xinyuan Zhang, Licheng Yang et autres

In the field of radar target recognition, the scarcity of non-cooperative target data and the limitations of traditional HRRP data enhancement methods have severely restricted the improvement of recognition accuracy. This paper aims to break through this predicament, propose an HRRP data …

cn (code pays fourni par la source)

VLM as Policy: Common-Law Content Moderation Framework for Short Video Platform

Xingyu Lu, Tianke Zhang, Chang Meng, X. Wang et autres

cn (code pays fourni par la source)

ROMA: Recommendation-Oriented Language Model Adaptation Using Multi-Modal Multi-Domain Item Sequences

Xingyu Lu, Jinpeng Wang, Jieming Zhu, Zhicheng Zhang et autres

Sequential recommendation (SR) aims to capture dynamic user preferences from users' historical behaviors. Recently, benefiting from astonishing understanding ability of pre-trained language models (PLMs), text-enhanced sequential recommender becomes a promising direction, which employs PLMs to extract semantic information for user/item representation. Although …

cn (code pays fourni par la source)

PAI-1 regulates extracellular matrix remodeling and alters fibroblast profibrotic ability in skeletal muscle repair

Na Li, Xingyu Lu, Jieyun Zhang, Li-hong Dang et autres

cn, us (code pays fourni par la source)

PD-L1 antibody-modified plant-derived nanovesicles carrying a STING agonist for the combinational immunotherapy of melanoma

Zhanxue Xu, Xinrui Yang, Xingyu Lu, Dandan Su et autres

ABSTRACT Combination therapies for melanoma face challenges due to asynchronous drug delivery and associated toxicity, underscoring the need for advanced delivery systems. While immune checkpoint inhibitors (ICIs) enhance T cell activity, optimal cytotoxic responses require efficient antigen presentation by mature dendritic cells …

cn (code pays fourni par la source)

Durvalumab‑induced type 1 diabetes mellitus in lung adenocarcinoma: A case report and literature review

Huijing Dong, Shengfu Li, Yanmei Peng, Xu Zhang et autres

Immune checkpoint inhibitor-induced type 1 diabetes mellitus (ICI-T1DM) is a rare adverse reaction associated with durvalumab. Among the adverse reactions to durvalumab, the incidence of new-onset diabetes is relatively rare, occurring in ~0.2% of cases. The present study reports the case of …

cn (code pays fourni par la source)

Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: a systematic review and meta-analysis

Kexin Tan, Aolin Wang, Yumin Zheng, Shuo Wang et autres

cn (code pays fourni par la source)

Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions

Yixuan Yu, Shuo Wang, Zhening Liu, Xu Zhang et autres

Immune checkpoint inhibitors (ICIs) have revolutionized cancer management and have been widely applied; however, they still have some limitations in terms of efficacy and toxicity. There are multiple treatment regimens in Traditional Chinese Medicine (TCM) that play active roles in combination with …

cn (code pays fourni par la source)

A global meta-analysis of the correlation between soil physicochemical properties and lead bioaccessibility

Xingyu Lu, Qingchun Yang, Hao Wang, Yiwen Zhu

cn (code pays fourni par la source)

Spatial distribution, contamination characteristics and ecological-health risk assessment of toxic heavy metals in soils near a smelting area

Han Gui, Qingchun Yang, Xingyu Lu, Hualin Wang et autres

cn, es (code pays fourni par la source)

Changes of IL-6 And IFN-γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study

Xu Zhang, Xingyu Lu, Yixuan Yu, Kexin Tan et autres

Immune checkpoint inhibitors (ICIs) have changed the status of tumor immunotherapy. ICIs-related adverse events (irAEs) have the high incidence and are difficult to predict and prevent. Researches have suggested that changes of cytokines were associated with irAEs. This study focused on the …

cn, us (code pays fourni par la source)